Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

220
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
220
Drug Toxicity: Overview01:00

Drug Toxicity: Overview

295
Drug toxicity quantifies the harm a compound causes to an organism, varying by dose and potentially impacting whole systems or specific organs like the liver. Toxic reactions may arise from venomous insect or spider bites, with effects ranging from mild symptoms to severe outcomes such as brain damage or death. Common forms of acute poisoning include ethanol intoxication and overdose of pain or fever medications, with substances like GHB and heroin being particularly lethal at doses close to...
295
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

229
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
229
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

379
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
379
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

229
Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
229
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

818
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
818

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The gut-liver axis in drug-induced liver injury (DILI): Interplay between gut microbiota, intestinal barrier, and immune system.

Acta pharmaceutica Sinica. B·2026
Same author

Clinical Trial Registration and Transparency in No 536/2014:Europe under Regulation (EU): Registry Ecosystems and a Five-Country Comparative Analysis, 2022-2026.

Medicina clinica·2026
Same author

Systematic review on genetic polymorphisms associated with idiosyncratic drug-induced liver injury (iDILI): iDILInet as an interactive visualization tool.

Acta pharmaceutica Sinica. B·2026
Same author

Steatotic Liver Disease at Primary Biliary Cholangitis Diagnosis: Association With Ursodeoxycholic Acid Response and Outcomes.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

HLA-B*44 Alleles and HLA-DQA1*03:01 as Genetic Risk Factors for Drug-Induced Liver Injury due to Fluoroquinolones.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

An update on drug-induced liver injury-What's new?

Journal of internal medicine·2026

Related Experiment Video

Updated: May 4, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

7.6K

Idiosyncratic drug hepatotoxicity: a 2008 update.

Raúl J Andrade1, Susana López-Ortega, M Carmen López-Vega

  • 1CIBERehd; Liver Unit, Gastroenterology Service, "Virgen de la Victoria" University Hospital and School of Medicine, Málaga, Spain. andrade@uma.es.

Expert Review of Clinical Pharmacology
|January 16, 2014
PubMed
Summary

Drug-induced liver injury (DILI) can cause severe liver disease, often idiosyncratic and unpredictable. Early detection and withdrawal of the offending drug are crucial for managing DILI.

More Related Videos

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
11:36

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

2.5K
Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

661

Related Experiment Videos

Last Updated: May 4, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

7.6K
Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
11:36

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

2.5K
Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

661

Area of Science:

  • Hepatology
  • Pharmacology
  • Toxicology

Background:

  • Pharmaceuticals, herbal products, and supplements contribute to severe liver disease.
  • Acetaminophen is a common cause of drug-induced liver injury (DILI), but idiosyncratic reactions are prevalent.
  • The rarity of DILI hinders detection in clinical trials, and its pathogenesis remains unclear, likely involving drug metabolism and immune activation.

Purpose of the Study:

  • To review the current understanding of drug-induced liver injury (DILI).
  • To discuss the clinical presentation, risk factors, and long-term consequences of DILI.
  • To explore diagnostic challenges and therapeutic strategies for DILI.

Main Methods:

  • Review of existing literature and databases on drug-induced liver injury.
  • Analysis of pooled data to identify risk factors and clinical patterns.
  • Evaluation of diagnostic tools and causality assessment methods.

Main Results:

  • Antibiotics, NSAIDs, and anticonvulsants are frequently implicated in DILI.
  • DILI presents as hepatocellular, cholestatic, or mixed liver damage, influenced by age and gender.
  • Older age is linked to cholestatic/mixed injury, while female gender, older age, AST, and bilirubin levels correlate with hepatocellular injury and severe outcomes.
  • Chronic liver damage occurs in at least 6% of survivors, with cardiovascular and CNS drugs being common culprits.
  • The Council for International Organizations of Medical Sciences/Roussel Uclaf Causality Assessment Method is the gold standard for causality assessment.

Conclusions:

  • Diagnosing DILI is challenging due to a lack of reliable biomarkers.
  • Development of improved diagnostic algorithms and abridged assessment tools is needed.
  • Supportive care and early withdrawal of the causative agent are the cornerstones of DILI management.